Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 08:50:50 24/05/2024 pm IST			5-day change	1st Jan Change
42.02 ^EUR	-0.77%		-5.64%	-25.89%

25/04	Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/03	Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	MT

Formycon AG Provides Revenue Guidance for the Fiscal Year of 2020

November 11, 2020 at 12:00 pm IST

Formycon AG provided Revenue Guidance for the Fiscal Year of 2020. For the year, The company expects Group revenues for 2020 be EUR 35.0 to EUR 40.0 million.

Latest news about Formycon AG

Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	18/03	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	18/03	DJ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	11/03	MT
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	30/01	MT
EU Medicines Regulator Accepts Formycon's Marketing Authorization Application for Eylea Biosimilar	27/12	MT
Formycon JV Wins Canadian Approval for Retinal Diseases Treatment Ranopto	07/12	MT
Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. Announces Health Canada Approves FYB201/Ranopto (Ranibizumab)	07/12	CI
US FDA Accepts for Review Formycon, Fresenius' Biologics License Application for Stelara Biosimilar	30/11	MT
Novartis AG : Sandoz takes its first steps on the stock exchange	04/23/04
EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate	29/23/29	MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2023	30/23/30	CI
US FDA Accepts Formycon's Biologics License Application for Eylea Biosimilar	29/23/29	MT
Formycon, Fresenius to Launch Biosimilar for Johnson & Johnson's Anti-inflammatory Drug by 2025	07/23/07	MT
Certain Shares of Formycon AG are subject to a Lock-Up Agreement Ending on 2-AUG-2023.	02/23/02	CI
Formycon Announces Submission of the Biologics License Application for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration	29/23/29	CI
Jefferies starts Formycon with 'Buy' - Target 101 euros	22/23/22	DP
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Formycon AG Provides Earnings Guidance for the Year 2023	27/23/27	CI
Formycon Concludes Clinical Development of Stelara Biosimilar; Regulatory Filings Expected in Q3	25/23/25	MT
Formycon AG Announces Successful Results of Phase I Clinical Trial for Ustekinumab Biosimilar Candidate FYB202 and Concludes Clinical Development	25/23/25	CI
Formycon's Interim Analysis of Late-stage Trial of Aflibercept Biosimilar Candidate Shows Efficacy Against Macular Degeneration	06/23/06	MT
Formycon Raises EUR70 Million to Fund Biosimilar Candidates' Development	02/23/02	MT
Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit	02/23/02	MT
Strong Demand Prompts Formycon to Boost Size of Capital Increase	02/23/02	MT

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Formycon AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.35 EUR

Average target price

86 EUR

Spread / Average Target

+103.07%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FORMYCON AG	-25.89%	81Cr
MODERNA, INC.	+65.36%	6.29TCr
IQVIA HOLDINGS INC.	-1.03%	4.14TCr
LONZA GROUP AG	+45.83%	4.04TCr
CELLTRION, INC.	-8.93%	2.76TCr
ICON PUBLIC LIMITED COMPANY	+14.08%	2.65TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.52%	1.89TCr
BIO-TECHNE CORPORATION	+3.82%	1.27TCr
UNITED THERAPEUTICS CORPORATION	+23.29%	1.23TCr
MEDPACE HOLDINGS, INC.	+28.72%	1.21TCr

Other Biotechnology & Medical Research

Formycon AG

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Formycon AG Provides Revenue Guidance for the Fiscal Year of 2020

Latest news about Formycon AG

Chart Formycon AG

Company Profile

Income Statement Evolution

Ratings for Formycon AG

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research